EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Versatile Imidazole Scaffold with Potent Activity against Multiple Apicomplexan Parasites

Monique Khim, Jemma Montgomery, Mariana Laureano De Souza, Melvin Delvillar, Lyssa J Weible, Mayuri Prabakaran, Matthew A Hulverson iD, Tyler Eck, Rammohan Y Bheemanabonia, P Holland Alday, David P Rotella iD, J Stone Doggett iD und 3 weitere

ACS Infectious Diseases · 2025

DOI: 10.1021/acsinfecdis.5c00049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von Monique Khim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Seattle Structural Genomics Center for Infectious Disease, Seattle, Washington 98109, United States. Hauptthemen laut MEDLINE: Toxoplasma, Cryptosporidium parvum, Imidazoles, Plasmodium falciparum. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAID NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria, toxoplasmosis, and cryptosporidiosis are caused by apicomplexan parasites Plasmodium spp., Toxoplasma gondii, and Cryptosporidium parvum, respectively, and pose major health challenges. Their therapies are inadequate, ineffective or threatened by drug resistance. The development of novel drugs against them requires innovative and resource-efficient strategies. We exploited the kinome conservation of these parasites to determine the cellular targets and effects of two Plasmodium falciparum inhibitors in T. gondii and C. parvum. The imidazoles, (R)-RY-1-165 and (R)-RY-1-185, were developed to target the cGMP dependent protein kinase of P. falciparum (PfPKG), orthologs of which are present in T. gondii and C. parvum. Using structural and modeling approaches we determined that the molecules bind stereospecifically and interact with PfPKG in a manner unique among described inhibitors. We used enzymatic assays and mutant P. falciparum expressing PfPKG with a substituted "gatekeeper" residue to determine that cellular activity of the molecules is mediated through targets additional to PfPKG. These likely include P. falciparum calcium dependent protein kinase 1 and 4 (PfCDPK-1, -4), kinases that, like PfPKG, have small amino acids at the "gatekeeper" position. The molecules are active against T. gondii and C. parvum, with T. gondii tachyzoites being particularly sensitive. Using mutant parasites, enzyme assays and modeling studies we demonstrate that targets in T. gondii include TgPKG, TgCDPK1, TgCDPK4 and the mitogen activated kinase-like 1 (MAPKL-1). Our results suggest that this scaffold holds promise for the development of new toxoplasmosis drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmaCryptosporidium parvumImidazolesPlasmodium falciparumAntiprotozoal AgentsProtozoan ProteinsCyclic GMP-Dependent Protein KinasesHumans

Stichwörter der Autor:innen

PlasmodiumToxoplasmaapicomplexadrugskinase

Substanzen

ImidazolesProtozoan ProteinsAntiprotozoal AgentsCyclic GMP-Dependent Protein Kinases

Autor:innen und Institutionen

  • Seattle Structural Genomics Center for Infectious Disease, Seattle, Washington 98109, United States.
  • Center for Global Infectious Disease ResearchSeattle Children's Research Institute, Seattle, Washington 98109, United States.
  • Divisions of Infectious Diseases and ResearchVA Portland Healthcare System, Portland, Oregon 97239, United States.
  • Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey 07103, United States.
  • Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious DiseasesUniversity of Washington, Seattle, Washington 98109, United States.
  • Department of Chemistry and Biochemistry and Sokol Institute of Pharmaceutical Life SciencesMontclair State University, Montclair, New Jersey 07043, United States.

ORCID-Profile: Matthew A Hulverson, David P Rotella, J Stone Doggett, Bart L Staker, Purnima Bhanot

Förderung

  • BLRD VA
  • NIAID NIH HHS
  • NICHD NIH HHS
  • U.S. Department of Veterans Affairs
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Child Health and Human Development
  • U.S. Department of Defense

Zitieren

APA

Khim, M., Montgomery, J., Laureano De Souza, M., Delvillar, M., Weible, L. J., Prabakaran, M., Hulverson, M. A., Eck, T., Bheemanabonia, R. Y., Alday, P. H., Rotella, D. P., Doggett, J. S., Staker, B. L., Ojo, K. K., & Bhanot, P. (2025). Versatile Imidazole Scaffold with Potent Activity against Multiple Apicomplexan Parasites. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.5c00049

Vancouver

Khim M, Montgomery J, Laureano De Souza M, Delvillar M, Weible LJ, Prabakaran M, et al. Versatile Imidazole Scaffold with Potent Activity against Multiple Apicomplexan Parasites. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.5c00049

BibTeX
@article{Khim2025,
  author = {Khim, Monique and Montgomery, Jemma and Laureano De Souza, Mariana and Delvillar, Melvin and Weible, Lyssa J and Prabakaran, Mayuri and Hulverson, Matthew A and Eck, Tyler and Bheemanabonia, Rammohan Y and Alday, P Holland and Rotella, David P and Doggett, J Stone and Staker, Bart L and Ojo, Kayode K and Bhanot, Purnima},
  title = {Versatile Imidazole Scaffold with Potent Activity against Multiple Apicomplexan Parasites},
  journal = {ACS Infectious Diseases},
  year = {2025},
  doi = {10.1021/acsinfecdis.5c00049}
}
Kostenlos starten →